Briefing
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
Previously untreated CLL, age <70: 3 cycles ibrutinib then 12 cycles ibrutinib-venetoclax. Best uMRD 75% (PB) and 68% (BM). Patients with confirmed uMRD were randomized 1:1 to placebo or ibrutinib. 1-year DFS was 95% with placebo vs 100% with ibrutinib (difference 4.7%, 95% CI -1.6 to 10.9; P=0.15). Supports the potential for fixed-duration therapy after confirmed uMRD. Level 1 (MRD-guided randomized cohort).
- Design: paper
- n: Confirmed uMRD: 43 placebo, 43 ibrutinib
- Assay: Confirmed undetectable MRD used to randomize subsequent therapy (placebo vs ibrutinib)